Research Article
Controlling Nutritional Status (CONUT) as a Novel Postoperative Prognostic Marker in Breast Cancer Patients: A Retrospective Study
Table 4
The relationships between the CONUT score and pathological variables of BC patients.
| | Parameters | All patients (n=381) | | value | Control group (n=187) | | value | Treatment group (n=194) | | value | | Cases () | LOW 229 | HIGH 152 | Low 111 | High 76 | Low 118 | High 76 |
| | Postoperative pathology (IHC) | | | | | | | | | | | | | | Molecular subtype | | | 9.941 | 0.041 | | | 5.068 | 0.280 | | | 12.004 | 0.017 | | Luminal A | 17(58.62%) | 12(41.38%) | | | 10(76.92%) | 3(23.08%) | | | 7(43.75%) | 9(56.25%) | | | | Luminal B HER2+ | 19(48.72%) | 20(51.28%) | | | 10(55.56%) | 8(44.44%) | | | 9(42.86%) | 12(57.14%) | | | | Luminal B HER2- | 119(68.39%) | 55(31.61%) | | | 60(63.83%) | 34(36.17%) | | | 59(73.75%) | 21(26.25%) | | | | HER2 enriched | 36(54.55%) | 30(45.45%) | | | 14(46.67%) | 16(53.33%) | | | 22(61.11%) | 14(38.89%) | | | | Triple negative | 38(52.05%) | 35(47.95%) | | | 17(53.13%) | 15(46.88%) | | | 21(51.22%) | 20(48.78%) | | | | ER status | | | 10.393 | 0.016 | | | 9.187 | 0.027 | | | 4.253 | 0.235 | | 0-25% | 89(51.74%) | 83(48.26%) | | | 42(49.41%) | 43(50.59%) | | | 47(54.02%) | 40(45.98%) | | | | 26-50% | 35(71.43%) | 14(28.57%) | | | 26(78.79%) | 7(21.21%) | | | 9(56.25%) | 7(43.75%) | | | | 51-75% | 19(73.08%) | 7(26.92%) | | | 7(70.00%) | 3(30.00%) | | | 12(75.00%) | 4(25.00%) | | | | 76-100% | 86(64.18%) | 48(35.82%) | | | 36(61.02%) | 23(38.98%) | | | 50(66.67%) | 25(33.33%) | | | | PR status | | | 9.655 | 0.022 | | | 8.214 | 0.042 | | | 3.681 | 0.298 | | 0-25% | 129(55.13%) | 105(44.87%) | | | 49(50.52%) | 48(49.48%) | | | 80(58.39%) | 57(41.61%) | | | | 26-50% | 47(75.81%) | 15(24.19%) | | | 27(75.00%) | 9(25.00%) | | | 20(76.92%) | 6(23.08%) | | | | 51-75% | 16(69.57%) | 7(30.43%) | | | 7(77.78%) | 2(22.22%) | | | 9(64.29%) | 5(35.71%) | | | | 76-100% | 37(59.68%) | 25(40.32%) | | | 28(62.22%) | 17(37.78%) | | | 9(52.94%) | 8(47.06%) | | | | HER2 status | | | 2.160 | 0.141 | | | 2.344 | 0.126 | | | 0.364 | 0.546 | | Negative (0--++) | 171(62.41%) | 103(37.59%) | | | 87(62.59%) | 52(37.41%) | | | 84(62.22%) | 51(37.78%) | | | | Positive (+++) | 58(54.21%) | 49(45.79%) | | | 24(50.00%) | 24(50.00%) | | | 34(57.63%) | 25(42.37%) | | | | Ki-67 status | | | 8.813 | 0.032 | | | 6.221 | 0.101 | | | 4.863 | 0.182 | | 0-25% | 148(66.37%) | 75(33.63%) | | | 85(64.89%) | 46(35.11%) | | | 63(68.48%) | 29(31.52%) | | | | 26-50% | 52(51.49%) | 49(48.51%) | | | 18(43.90%) | 23(56.10%) | | | 34(56.67%) | 26(43.33%) | | | | 51-75% | 18(51.43%) | 17(48.57%) | | | 6(50.00%) | 6(50.00%) | | | 12(52.17%) | 11(47.83%) | | | | 76-100% | 11(50.00%) | 11(50.00%) | | | 2(66.67%) | 1(33.33%) | | | 9(47.37%) | 10(52.63%) | | | | AR status | | | 2.901 | 0.407 | | | | | | | 2.855 | 0.414 | | 0-25% | 221(59.73%) | 149(40.27%) | | | 111(59.36%) | 76(40.64%) | | | 110(60.11%) | 73(39.89%) | | | | 26-50% | 2(66.67%) | 1(33.33%) | | | 0(0.00%) | 0(0.00%) | | | 2(66.67%) | 1(33.33%) | | | | 51-75% | 4(100.00%) | 0(0.00%) | | | 0(0.00%) | 0(0.00%) | | | 4(100.00%) | 0(0.00%) | | | | 76-100% | 2(50.00%) | 2(50.00%) | | | 0(0.00%) | 0(0.00%) | | | 2(50.00%) | 2(50.00%) | | | | P53 status | | | 7.605 | 0.055 | | | 11.823 | 0.008 | | | 7.181 | 0.066 | | 0-25% | 179(64.16%) | 100(35.84%) | | | 91(63.19%) | 53(36.81%) | | | 88(65.19%) | 47(34.81%) | | | | 26-50% | 18(51.43%) | 17(48.57%) | | | 7(70.00%) | 3(30.00%) | | | 11(44.00%) | 14(56.00%) | | | | 51-75% | 29(46.77%) | 33(53.23%) | | | 10(33.33%) | 20(66.67%) | | | 19(59.38%) | 13(40.63%) | | | | 76-100% | 3(60.00%) | 2(40.00%) | | | 3(100.00%) | 0(0.00%) | | | 0(0.00%) | 2(100.00%) | | | | TOP2A status | | | 10.133 | 0.017 | | | 6.524 | 0.038 | | | 6.182 | 0.103 | | 0-25% | 187(63.39%) | 108(36.61%) | | | 96(63.58%) | 55(36.42%) | | | 91(63.19%) | 53(36.81%) | | | | 26-50% | 38(52.05%) | 35(47.95%) | | | 15(42.86%) | 20(57.14%) | | | 23(60.53%) | 15(39.47%) | | | | 51-75% | 3(25.00%) | 9(75.00%) | | | 0(0.00%) | 1(100.00%) | | | 3(27.27%) | 8(72.73%) | | | | 76-100% | 1(100.00%) | 0(0.00%) | | | 0(0.00%) | 0(0.00%) | | | 1(100.00%) | 0(0.00%) | | | | CK5/6 status | | | 1.693 | 0.193 | | | 0.001 | 0.976 | | | 2.395 | 0.122 | | Negative | 211(61.16%) | 134(38.84%) | | | 108(59.34%) | 74(40.66%) | | | 103(63.19%) | 60(36.81%) | | | | Positive | 18(50.00%) | 18(50.00%) | | | 3(60.00%) | 2(40.00%) | | | 15(48.39%) | 16(51.61%) | | | | E-cad status | | | 0.042 | 0.838 | | | 2.183 | 0.140 | | | 0.294 | 0.588 | | Negative | 138(60.53%) | 90(39.47%) | | | 99(61.49%) | 62(38.51%) | | | 39(58.21%) | 28(41.79%) | | | | Positive | 91(59.48%) | 62(40.52%) | | | 12(46.15%) | 14(53.85%) | | | 79(62.20%) | 48(37.80%) | | | | EGFR status | | | 3.092 | 0.079 | | | 0.303 | 0.582 | | | 3.738 | 0.053 | | Negative | 194(62.18%) | 118(37.82%) | | | 107(59.78%) | 72(40.22%) | | | 87(65.41%) | 46(34.59%) | | | | Positive | 35(50.72%) | 34(49.28%) | | | 4(50.00%) | 4(50.00%) | | | 31(50.82%) | 30(49.18%) | | | | Lymph vessel invasion | | | 0.712 | 0.399 | | | 1.907 | 0.167 | | | 0.312 | 0.860 | | Negative | 144(58.54%) | 102(41.46%) | | | 68(55.74%) | 54(44.26%) | | | 76(61.29%) | 48(38.71%) | | | | Positive | 85(62.96%) | 50(37.04%) | | | 43(66.15%) | 22(33.85%) | | | 42(60.00%) | 28(40.00%) | | | | Neural invasion | | | 0.340 | 0.560 | | | 0.001 | 0.976 | | | 0.582 | 0.445 | | Negative | 202(60.66%) | 131(39.34%) | | | 108(59.34%) | 74(40.66%) | | | 94(62.25%) | 57(37.75%) | | | | Positive | 27(56.25%) | 21(43.75%) | | | 3(60.00%) | 2(40.00%) | | | 24(55.81%) | 19(44.19%) | | |
|
|
#ER: estrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor receptor; AR: androgen receptor, E-cad: e-cadnerin; EGFR: epithelial growth factor receptor.
|
